with glandular disease [1]. When compared with omeprazole; esomeprazole, the S-enantiomer of omeprazole, has a lower first-pass hepatic metabolism, slower plasma clearance, higher peak plasma concentration, higher area under the plasma concentration-time curve and greater clinical efficacy in man. In horses, esomeprazole suppresses gastric acid production for longer than omeprazole [2]; however, efficacy in clinical cases has not been reported. Objectives: To report the outcome of esomeprazole treatment for squamous and glandular gastric disease in horses that had failed to respond to treatment with omeprazole. Study design: Case series. Methods: Regular clinical examinations and gastroscopy were performed in five horses that were treated with omeprazole (4 mg/kg per os s.i.d.) and, in the absence of improvement, were treated subsequently with esomeprazole (2 mg/kg per os s.i.d.). Management and dietary recommendations remained consistent throughout the treatment period although levels of compliance varied. Results: Esomeprazole treatment was associated with resolution of squamous and glandular gastric disease in 4/5 horses. Conclusions: Esomeprazole may be a more effective treatment for squamous and glandular gastric disease than omeprazole. Blinded case-controlled studies with larger numbers of horses are warranted. Ethical animal research: Informed client consent was obtained. Abstracts Objectives: To describe the surrounding circumstances, clinical signs, progression and outcome of i.v. catheter-associated air embolism in hospitalised horses. Study design: Multicentre retrospective study.